XML 72 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6
Major Customers, Partnerships and Strategic Alliances (Details Textual) (USD $)
 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Oct. 31, 2009
California Institute for Regenerative Medicine [Member]
Dec. 31, 2012
California Institute for Regenerative Medicine [Member]
Dec. 31, 2011
California Institute for Regenerative Medicine [Member]
Dec. 31, 2010
California Institute for Regenerative Medicine [Member]
Apr. 30, 2011
CHDI Foundation, Inc. [Member]
Dec. 31, 2012
CHDI Foundation, Inc. [Member]
Dec. 31, 2011
CHDI Foundation, Inc. [Member]
Jan. 31, 2007
Michael J. Fox Foundation for Parkinson's Research [Member]
Dec. 31, 2012
Michael J. Fox Foundation for Parkinson's Research [Member]
Mar. 31, 2012
Juvenile Diabetes Research Foundation International [Member]
Oct. 31, 2006
Juvenile Diabetes Research Foundation International [Member]
Dec. 31, 2012
Qualifying Therapeutic Discovery Project Program [Member]
Dec. 31, 2011
Qualifying Therapeutic Discovery Project Program [Member]
Dec. 31, 2010
Qualifying Therapeutic Discovery Project Program [Member]
Jun. 30, 2012
Shire AG [Member]
Targets
Jan. 31, 2012
Shire AG [Member]
Targets
Dec. 31, 2012
Shire AG [Member]
Oct. 31, 2009
Sigma-Aldrich Corporation [Member]
Jul. 31, 2007
Sigma-Aldrich Corporation [Member]
Dec. 31, 2012
Sigma-Aldrich Corporation [Member]
Dec. 31, 2011
Sigma-Aldrich Corporation [Member]
Dec. 31, 2010
Sigma-Aldrich Corporation [Member]
Dec. 31, 2009
Sigma-Aldrich Corporation [Member]
Oct. 31, 2005
Dow AgroSciences [Member]
Dec. 31, 2012
Dow AgroSciences [Member]
Dec. 31, 2011
Dow AgroSciences [Member]
Dec. 31, 2010
Dow AgroSciences [Member]
Dec. 31, 2012
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Dec. 31, 2011
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Dec. 31, 2010
License agreement terms [Member]
California Institute for Regenerative Medicine [Member]
Dec. 31, 2012
License agreement terms [Member]
Michael J. Fox Foundation for Parkinson's Research [Member]
Dec. 31, 2011
License agreement terms [Member]
Michael J. Fox Foundation for Parkinson's Research [Member]
Dec. 31, 2010
License agreement terms [Member]
Michael J. Fox Foundation for Parkinson's Research [Member]
Dec. 31, 2012
License agreement terms [Member]
Juvenile Diabetes Research Foundation International [Member]
Dec. 31, 2011
License agreement terms [Member]
Juvenile Diabetes Research Foundation International [Member]
Dec. 31, 2010
License agreement terms [Member]
Juvenile Diabetes Research Foundation International [Member]
Dec. 31, 2012
License agreement terms [Member]
Sigma-Aldrich Corporation [Member]
Dec. 31, 2011
License agreement terms [Member]
Sigma-Aldrich Corporation [Member]
Dec. 31, 2010
License agreement terms [Member]
Sigma-Aldrich Corporation [Member]
Oct. 31, 2009
License agreement terms [Member]
Sigma-Aldrich Corporation [Member]
Oct. 31, 2005
License agreement terms [Member]
Dow AgroSciences [Member]
Jan. 31, 2007
Additional Funding Agreement Terms [Member]
Michael J. Fox Foundation for Parkinson's Research [Member]
Jun. 30, 2010
Additional Funding Agreement Terms [Member]
Michael J. Fox Foundation for Parkinson's Research [Member]
Oct. 31, 2006
Additional Funding Agreement Terms [Member]
Juvenile Diabetes Research Foundation International [Member]
Oct. 31, 2009
Upfront license fee [Member]
Sigma-Aldrich Corporation [Member]
Oct. 31, 2005
Maximum [Member]
Dow AgroSciences [Member]
Oct. 31, 2005
Minimum [Member]
Dow AgroSciences [Member]
Major Customers, Partnerships and Strategic Alliances (Textual) [Abstract]                                                                                                    
Aggregate number of gene targets                                     7                                                              
Number of gene targets                                   5                                                                
Number of initial gene targets                                     4                                                              
Number of additional gene targets                                   2                                                                
Research program to develop laboratory research reagents                                       6 years   3 years         3 years                                              
Upfront license fee                                       $ 13,000,000 $ 20,000,000                                                     $ 15,100,000    
Expected amount to be received for research and development       5,200,000                               213,500,000                                                            
IND or CTA submission amount                                       8,500,000                                                            
Royalty revenues                                       0     1,288,000 938,000 734,000   2,300,000                                 4,000,000            
Deferred revenue 2,304,000 17,000                                   11,100,000                                                            
Collaboration Agreement Related Costs and Expenses         1,200,000 2,000,000 1,000,000   1,100,000 1,200,000                                                                                
Common stock, valued                                         4,900,000                                                          
Public offering, common stock shares issued                                                   636,133                                                
Royalty revenues expected to be received                                                                                     5,000,000              
Reduced royalty rate                                         10.50%                                                          
Funding available under the amended agreement                                         25,000,000                                                          
Related costs and expenses                                       7,700,000               600,000 900,000 700,000                   300,000 500,000 1,200,000                
One time license fee earned on exercise of option                                                     6,000,000                                              
Percentage of royalties to be received from sublicensing                                                     25.00%                                              
Funds due under agreement               1,300,000                                                                                    
Annual fees                                                                                                 3,000,000 250,000
Minimum sublicense annual fees specific reckoning period                                                     11 years                                              
Fee due                                                     25,300,000                                              
Agreement date       2009-10       2011-04     2007-01     2006-10                                                                        
Funds due under the agreement       14,500,000                                                                                 1,000,000          
Agreement to receive       4 years       1 year                                                                                    
Receivables from sale against the grant funded to entity from sale of product         2                                                                                          
Revenues under the agreement                 1,100,000 1,100,000         0 0 1,000,000                           1,200,000 1,700,000 1,000,000 0 400,000 400,000 800,000 500,000 1,500,000                      
Grant funding amount maximum under amended agreement.                                                                                             3,000,000      
Received for work performed under agreement                         800,000                                                                          
Revenue attributable to research and development                                             1,000,000 671,000 11,574,000     4,700,000 4,500,000 4,400,000                                        
Funding received from research grant.                       1,900,000                                                                   900,000        
Research grants 3,469,000 4,209,000 3,986,000                                                                                              
Funds due under agreement as per amendment                 $ 2,100,000                                                                                  
Contractual agreement termination date                 Aug. 31, 2012